Jose Genolla1, Trinidad Rodriguez2, Pablo Minguez3, Ricardo Lopez-Almaraz4, Veronica Llorens2, Aizpea Echebarria4. 1. Department of Nuclear Medicine, Cruces University Hospital, Plaza de Cruces s/n, 48903, Baracaldo, Vizcaya, Spain. jose.genollasubirats@osakidetza.eus. 2. Department of Nuclear Medicine, Cruces University Hospital, Plaza de Cruces s/n, 48903, Baracaldo, Vizcaya, Spain. 3. Department of Medical Physics and Radiation Protection, Cruces University Hospital, Plaza de Cruces s/n, 48903, Baracaldo, Vizcaya, Spain. 4. Department of Pediatric Oncology and Hematology, Cruces University Hospital, Plaza de Cruces s/n, 48903, Baracaldo, Vizcaya, Spain.
Abstract
PURPOSE: Patients with high-risk neuroblastoma have an increased risk of recurrence and relapse of disease and a very poor prognosis. 131I-metaiodobenzylguanidine (131I-mIBG) in combination with topotecan as a radiosensitizer can be an effective and relatively well-tolerated agent for the treatment of refractory neuroblastoma. The aim of this retrospective study was to evaluate response and outcome of combined therapy with 131I-mIBG and topotecan. METHODS: Ten patients, between 3 and 20 years of age, were included. Nine patients had been refractory to several lines of chemotherapy and radiotherapy. One patient with a very high-risk neuroblastoma had received only induction therapy. Response was graded according to the International Neuroblastoma Staging System. RESULTS: Regarding treatment response, two patients achieved complete remission, one with relapse at 16 months, five achieved a partial remission, four showed progression at between 1 and 18 months; two showed stable disease with progression at between 1 and 5 months, and one showed progressive disease. Eight of the ten patients died with overall survival between 4 and 63 months, and two patients were still alive without disease at the time of this report: 52 and 32 months (patient had received only induction therapy). Acute and subacute adverse effects were mainly haematological, and one patient developed a differentiated thyroid cancer. CONCLUSION: In patients with high-risk refractory neuroblastoma, administration of high activities of 131I-mIBG in combination with topotecan was found to be an effective therapy, increasing overall survival and progression-free survival. Further studies including a larger number of patients and using 131I-mIBG for first-line up-front therapy are warranted.
PURPOSE:Patients with high-risk neuroblastoma have an increased risk of recurrence and relapse of disease and a very poor prognosis. 131I-metaiodobenzylguanidine (131I-mIBG) in combination with topotecan as a radiosensitizer can be an effective and relatively well-tolerated agent for the treatment of refractory neuroblastoma. The aim of this retrospective study was to evaluate response and outcome of combined therapy with 131I-mIBG and topotecan. METHODS: Ten patients, between 3 and 20 years of age, were included. Nine patients had been refractory to several lines of chemotherapy and radiotherapy. One patient with a very high-risk neuroblastoma had received only induction therapy. Response was graded according to the International Neuroblastoma Staging System. RESULTS: Regarding treatment response, two patients achieved complete remission, one with relapse at 16 months, five achieved a partial remission, four showed progression at between 1 and 18 months; two showed stable disease with progression at between 1 and 5 months, and one showed progressive disease. Eight of the ten patientsdied with overall survival between 4 and 63 months, and two patients were still alive without disease at the time of this report: 52 and 32 months (patient had received only induction therapy). Acute and subacute adverse effects were mainly haematological, and one patient developed a differentiated thyroid cancer. CONCLUSION: In patients with high-risk refractory neuroblastoma, administration of high activities of 131I-mIBG in combination with topotecan was found to be an effective therapy, increasing overall survival and progression-free survival. Further studies including a larger number of patients and using 131I-mIBG for first-line up-front therapy are warranted.
Authors: Mary Lou Schmidt; Ashutosh Lal; Robert C Seeger; John M Maris; Hiroyuki Shimada; Maura O'Leary; Robert B Gerbing; Katherine K Matthay Journal: J Clin Oncol Date: 2005-08-22 Impact factor: 44.544
Authors: Edward F Attiyeh; Wendy B London; Yael P Mossé; Qun Wang; Cynthia Winter; Deepa Khazi; Patrick W McGrady; Robert C Seeger; A Thomas Look; Hiroyuki Shimada; Garrett M Brodeur; Susan L Cohn; Katherine K Matthay; John M Maris Journal: N Engl J Med Date: 2005-11-24 Impact factor: 91.245
Authors: Mark N Gaze; Yen-Ch'ing Chang; Glenn D Flux; Rob J Mairs; Frank H Saran; Simon T Meller Journal: Cancer Biother Radiopharm Date: 2005-04 Impact factor: 3.099
Authors: K K Matthay; J G Villablanca; R C Seeger; D O Stram; R E Harris; N K Ramsay; P Swift; H Shimada; C T Black; G M Brodeur; R B Gerbing; C P Reynolds Journal: N Engl J Med Date: 1999-10-14 Impact factor: 91.245
Authors: Sean Carlin; Rob J Mairs; Anthony G McCluskey; Deborah A Tweddle; Alan Sprigg; Christine Estlin; Julian Board; Rani E George; Caroline Ellershaw; Andrew D J Pearson; John Lunec; Paolo G Montaldo; Mirco Ponzoni; Berthe L van Eck-Smit; Cees A Hoefnagel; Marieke D van den Brug; Godelieve A M Tytgat; Huib N Caron Journal: Clin Cancer Res Date: 2003-08-15 Impact factor: 12.531
Authors: S Miyamoto; T T Huang; S Wuerzberger-Davis; W G Bornmann; J J Pink; C Tagliarino; T J Kinsella; D A Boothman Journal: Ann N Y Acad Sci Date: 2000 Impact factor: 6.499
Authors: S Mastrangelo; A Tornesello; L Diociaiuti; A Pession; A Prete; V Rufini; L Troncone; R Mastrangelo Journal: Br J Cancer Date: 2001-02 Impact factor: 7.640
Authors: A Garaventa; O Bellagamba; M S Lo Piccolo; C Milanaccio; E Lanino; L Bertolazzi; G P Villavecchia; M Cabria; G Scopinaro; F Claudiani; B De Bernardi Journal: Br J Cancer Date: 1999-12 Impact factor: 7.640
Authors: L Kölby; P Bernhardt; A-M Levin-Jakobsen; V Johanson; B Wängberg; H Ahlman; E Forssell-Aronsson; O Nilsson Journal: Br J Cancer Date: 2003-10-06 Impact factor: 7.640
Authors: Jianhua Feng; Frankie Wt Cheng; Alex Wk Leung; Vincent Lee; Eva Wm Yeung; Hoi Ching Lam; Jeanny Cheung; Grace Ks Lam; Terry Tw Chow; Carol Ls Yan; Chi Kong Li Journal: Pediatr Investig Date: 2020-09-27
Authors: Brian D Weiss; Gregory Yanik; Arlene Naranjo; Fan F Zhang; Wendy Fitzgerald; Barry L Shulkin; Marguerite T Parisi; Heidi Russell; Stephan Grupp; Luke Pater; Peter Mattei; Yael Mosse; Hollie A Lai; Jason A Jarzembowski; Hiroyuki Shimada; Judith G Villablanca; Roger Giller; Rochelle Bagatell; Julie R Park; Katherine K Matthay Journal: Pediatr Blood Cancer Date: 2021-05-24 Impact factor: 3.838